Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials

  • Ying, Min (Department of Radiation Oncology, Nanfang Hospital, Southern Medical University) ;
  • Zhu, Xiao-Xia (Department of Radiation Oncology, Nanfang Hospital, Southern Medical University) ;
  • Zhao, Yang (The First Clinical Medical College, Nanfang Hospital, Southern Medical University) ;
  • Li, Dian-He (Department of Radiation Oncology, Nanfang Hospital, Southern Medical University) ;
  • Chen, Long-Hua (Department of Radiation Oncology, Nanfang Hospital, Southern Medical University)
  • Published : 2015.06.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Because there is no clear consensus for the prognostic implication of KRAS mutations in patients with non-small cell lung cancer (NSCLC), we conducted a meta-analysis based on 12 randomized trials to draw a more accurate conclusion. Materials and Methods: A systematic computer search of articles from inception to May 1, 2014 using the PubMed, EMBASE, and Cochrane databases was conducted. The enrollment of articles and extraction of data were independently performed by two authors. Results: Our analysis was based on the endpoints overall survival (OS) and progression-free survival (PFS). Nine records (All for OS, 7 for PFS) comprising 12 randomized trials were identified with 3701 patients who underwent a test for KRAS mutations. In the analysis of the pooled hazard ratios (HRs) for OS (HR: 1.39; 95% confidence interval [CI] 1.23-1.56) and PFS (HR: 1.33; 95% CI 1.17-1.51), we found that KRAS mutations are related to poor survival benefit for NSCLC. According to a subgroup analysis stratified by disease stage and line of therapy, the combined HRs for OS and PFS coincided with the finding that the presence of a KRAS mutation is a dismal prognostic factor. However, the prognostic role of KRAS mutations are not statistically significant in a subgroup analysis of patients treated with chemotherapy in combination with cetuximab based on the endpoints OS (P=0.141) and PFS (P=0.643). Conclusions: Our results indicate that KRAS mutations are associated with inferior survival benefits for NSCLC but not for those treated with chemotherapies integrating cetuximab.

Keywords

References

  1. Alimujiang S, Zhang T, Han Z-G, et al (2013). Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev, 14, 2413-9. https://doi.org/10.7314/APJCP.2013.14.4.2413
  2. Brugger W, Triller N, Blasinska-Morawiec M, et al (2011). Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol, 29, 4113-20. https://doi.org/10.1200/JCO.2010.31.8162
  3. Carney DN (2002). Lung Cancer-time to move on from chemotherapy. N Engl J Med, 346, 126-8. https://doi.org/10.1056/NEJM200201103460211
  4. Chetty R,Govender D (2013). Gene of the month: KRAS. J Clin Pathol, 66, 548-50. https://doi.org/10.1136/jclinpath-2013-201663
  5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  6. Douillard JY, Shepherd FA, Hirsh V, et al (2010). Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 28, 744-52. https://doi.org/10.1200/JCO.2009.24.3030
  7. Eberhard DA, Johnson BE, Amler LC, et al (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23, 5900-9. https://doi.org/10.1200/JCO.2005.02.857
  8. Goss GD, O'Callaghan C, Lorimer I, et al (2013). Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol, 31, 3320-6. https://doi.org/10.1200/JCO.2013.51.1816
  9. Graziano SL, Gamble GP, Newman NB, et al (1999). Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol, 17, 668-75. https://doi.org/10.1200/JCO.1999.17.2.668
  10. Herbst RS, Kelly K, Chansky K, et al (2010). Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advancedstage non-small-cell lung cancer: Southwest oncology group study S0342. J Clin Oncol, 28, 4747-54. https://doi.org/10.1200/JCO.2009.27.9356
  11. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  12. Huncharek M, Muscat J,Geschwind JF (1999). K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis, 20, 1507-10. https://doi.org/10.1093/carcin/20.8.1507
  13. Johnson ML, Sima CS, Chaft J, et al (2013). Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer, 119, 356-62. https://doi.org/10.1002/cncr.27730
  14. Khambata-Ford S, Harbison CT, Hart LL, et al (2010). Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/ carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 28, 918-27. https://doi.org/10.1200/JCO.2009.25.2890
  15. Liberati A, Altman DG, Tetzlaff J, et al (2009). The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med, 151, 65-94.
  16. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective. J Natl Cancer Inst, 22, 719-48.
  17. Martin P, Leighl NB, Tsao MS, Shepherd FA (2013). KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol, 8, 530-42. https://doi.org/10.1097/JTO.0b013e318283d958
  18. Mascaux C, Iannino N, Martin B, et al (2005). The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer, 92, 131-9. https://doi.org/10.1038/sj.bjc.6602258
  19. Meng D, Yuan M, Li X, et al (2013). Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer, 81, 1-10. https://doi.org/10.1016/j.lungcan.2013.03.019
  20. NCCN (2012). Clinical practice guidelines in oncology (NCCN Guidelines(R)): non-small cell lung cancer. Cochrane Database of Systematic Reviews 2014.
  21. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol, 13, 795-805.
  22. Pirker R (2013). EGFR-directed monoclonal antibodies in nonsmall cell lung cancer. Target Oncol, 8, 47-53. https://doi.org/10.1007/s11523-012-0244-7
  23. Qi W-X, Shen Z, Lin F, et al (2012). Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-82. https://doi.org/10.7314/APJCP.2012.13.10.5177
  24. Ramalingam SS, Owonikoko TK, Khuri FR (2011). Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin, 61, 91-112. https://doi.org/10.3322/caac.20102
  25. Riely GJ, Kris MG, Rosenbaum D, et al (2008). Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res, 14, 5731-4. https://doi.org/10.1158/1078-0432.CCR-08-0646
  26. Roberts PJ, Stinchcombe TE (2014). KRAS mutation: should we test for it, and does it matter? J Clin Oncol, 31, 1112-57.
  27. Santos E, Martin-Zanca D, Reddy EP, et al (1984). Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science, 223, 661-4. https://doi.org/10.1126/science.6695174
  28. Schiller JH, Adak S, Feins RH, et al (2001). Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol, 19, 448-57. https://doi.org/10.1200/JCO.2001.19.2.448
  29. Schiller JH, Gandara DR, Goss GD,Vokes EE (2013). Non-smallcell lung cancer: then and now. J Clin Oncol, 31, 981-3. https://doi.org/10.1200/JCO.2012.47.5772
  30. Shepherd FA, Domerg C, Hainaut P, et al (2013). Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol, 31, 2173-81. https://doi.org/10.1200/JCO.2012.48.1390
  31. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  32. Slebos RJ, Kibbelaar RE, Dalesio O, et al (1990). K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med, 323, 561-5. https://doi.org/10.1056/NEJM199008303230902
  33. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  34. Usuda K, Sagawa M, Motono N, et al (2014). Relationships between EGFR Mutation status of lung cancer and preoperative factors-are they predictive? Asian Pac J Cancer Prev, 15, 657-62. https://doi.org/10.7314/APJCP.2014.15.2.657
  35. Zhu CQ, da Cunha Santos G, Ding K, et al (2008). Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer institute of canada clinical trials group study BR.21. J Clin Oncol, 26, 4268-75. https://doi.org/10.1200/JCO.2007.14.8924

Cited by

  1. Management of skin toxicity caused by epidermal growth factor receptor inhibitors vol.15, pp.11, 2017, https://doi.org/10.11124/JBISRIR-2017-003407
  2. Genetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci vol.7, pp.2045-2322, 2017, https://doi.org/10.1038/srep42185
  3. -mutant NSCLC: latest evidence and clinical consequences vol.9, pp.9, 2017, https://doi.org/10.1177/1758834017719829